<DOC>
	<DOCNO>NCT02143388</DOCNO>
	<brief_summary>This randomize , control , multicenter phase II clinical trial . The purpose study evaluate acute toxicity efficacy concurrent cisplatin chemoradiation without capecitabine adjuvant chemotherapy local advance high risk nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Concurrent Cisplatin Chemoradiation With Without Capecitabine Adjuvant Chemotherapy Local Advanced High Risk Nasopharyngeal Carcinoma : Phase II Randomized Control Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Newly histologic diagnosis nasopharyngeal carcinoma ( WHO II/III ) Clinical stage III~IVb ( UICC 7th ) Meet least one factor :1 primary tumor SUVmax &gt; 10 18FFDG PET/CT ; 2 primary tumor volume＞30cm3 ; 3 mutiple metastatic cervical lymph node least one 's short diameter＞4cm ; 4 T4N2M0 ; 5 T14N3M0 ; 6 EBVDNA＞2×10E4 copy/l Range 18～70 year old WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT AST ＜ 2.5×ULN、bilirubin ＜ 1.5×ULN OSerum creatinine ＜ 1.5×ULN Central nervous system metastases Suitable local treatment Uncontrolled seizure disorder serious neurologic disease Clinically significant cardiac respiratory disease Drug alcohol addition Do full capacity civil act Severe complication , active infection Concurrent immunotherapy hormone therapy diseases Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Local advance</keyword>
	<keyword>high risk</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
</DOC>